Introduction {#Sec1}
============

The nasopharyngeal carcinoma (NPC) evolves from the epithelial cells in the nasopharynx (Jeyakumar et al. [@CR18]). A distinction is drawn between three different histological subgroups: keratinizing squamous cell carcinoma, squamous cell carcinoma without keratinizing, and undifferentiated lymphoepithelial carcinoma (Brennan [@CR3]). Pathogenesis of the undifferentiated carcinoma is highly associated with prior or acute infection with the Ebstein--Barr virus (Chu et al. [@CR8]). In some areas in South China, the incidence of NPC is about 80 of 100,000 people and NPC is a disease of the adult. Interestingly, in Western civilisation the incidence with 1 of 100,000 is much lower, but one-third of these patients are children (Licitra [@CR21]). 70% of patients with NPC have to be classified in locally advanced stages UICC III/IVA/B at the point of diagnosis (Brennan [@CR3]; Jeyakumar et al. [@CR18]). Because of the tumour location in the nasopharynx with possible infiltration in the base of the skull, a complete tumour resection in curative intent is difficult in many cases. Because of a known distinctive sensitivity of nasopharyngeal carcinomas in radiotherapy, irradiation is recommended in the curative treatment for NPC's in the first line (Lee et al. [@CR5]), and especially undifferentiated NPC should not be operated in principle. Thereby, radiotherapy alone was gold standard in curative treatment of NPC until the early 1990s (Song et al. [@CR41]). Since several studies showed that in locally advanced carcinomas the combination of radio- and chemotherapy (neoadjuvant and/or concomitant) resulted in better treatment outcome than irradiation alone (Baujat et al. [@CR1]; Huncharek and Kupelnick [@CR17]; Langendijk et al. [@CR19]; Yarney et al. [@CR46]), the combination of radio- and chemotherapy became standard procedure in the curative treatment of locally advanced (UICC stages III/IVA/B) NPC's in the late 1990s. However, the optimum chemotherapy regimen for the neoadjuvant as well as the concomitant chemotherapy has not been defined yet. Most of the reported schedules are cisplatin-based, sometimes as monotherapy, sometimes in combination with other agents like 5-FU or others (Chen et al. [@CR7]; M'Rabti et al. [@CR27]; Ma and Chan [@CR28]).

Another approach in the treatment of undifferentiated NPC besides radio(chemo)therapy is an immunotherapy with interferon-beta. First, it was used in the recurrent/metastatic situation showing a good tumour response (Dimery et al. [@CR13]; Mahjoubi et al. [@CR30]; Treuner et al. [@CR42]). Because of the promising results of these reports, Mertens et al. ([@CR31]) included an adjuvant immunotherapy with interferon-beta application for 6 months after radiochemotherapy in children treated in curative intent with radio- (UICC stage I/II) or radiochemotherapy (UICC stage III/IV) in the NPC-91-GPOH trial (Nasopharynxkarzinom-91-Gesellschaft für Pädiatrische Onkologie und Hämatologie) (Mertens et al. [@CR31], [@CR32]). In this protocol, 59 children were treated as follows. One stage II patient received irradiation as primary therapy. The other 58 patients received three courses of neoadjuvant chemotherapy with methotrexate, cisplatin, and 5-FU followed by radiotherapy. After irradiation, all patients were treated with interferon-beta for 6 months. In summary, all patients showed excellent local-regional control and overall survival rates of 91 and 95% after 9 years, respectively (Mertens et al. [@CR32]). Based on these results, a consecutive study for undifferentiated NPC in children started in 2003 (NPC-2003-GPOH; Nasopharynxkarzinom-2003-Gesellschaft für Pädiatrische Onkologie und Hämatologie) and is recruiting until today. In this protocol, low-risk patients (stage I or II) receive radiotherapy alone followed by intravenous interferon-beta for 6 months. Patients stage III/IVA/B receive three courses of neoadjuvant chemotherapy with cisplatin, folinic acid, and 5-FU followed by concomitant radiochemotherapy with two courses of cisplatin and adjuvant interferon-beta for 6 months.

Because of the encouraging results of the GPOH trials investigating adjuvant interferon-beta in childhood NPC treated with primary radiochemotherapy, we started to treat adult patients with undifferentiated NPC according to the GPOH-protocols with neoadjuvant chemotherapy, followed by radio(chemo)therapy and adjuvant interferon-beta at our department in 2001.

Aim of the present study was to analyse the outcome of NPCs in adult patients during the last 17 years at our institution with special regard to adjuvant interferon-beta in undifferentiated carcinomas. Our data show in accordance with the literature that adult patients with NPC can be cured with radio(chemo)therapy alone without surgery. Besides, all patients with undifferentiated carcinomas treated with adjuvant interferon-beta according to the GPOH-protocols are still alive. Based on the results of the GPOH-studies in children and the present work, further prospective trials are needed to establish the role of interferon-beta in the curative treatment of adult NPC.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

Between February 1992 and July 2008, 26 adult patients with carcinoma of the nasopharynx without distant metastases were treated at our department in curative intent. Patients were 21 males and 5 females. Patients' age ranged from 28 to 81 years (median 60 years). Disease was staged according to the Union Internationale Contre le Cancer/American Joint Committee on Cancer (UICC/AJCC) criteria (Sobin and Wittekind [@CR40]).

Two patients were in stage II, nine patients were in stage III, and 15 patients were in stage IV. Thereby, in 2 patients the primary tumour was staged as T1, in 6 patients as T2, in 5 patients as T3, and in 13 patients as T4. In summary, 20 patients presented with positive cervical lymph nodes (1 patient N1, 16 patients N2, and 3 patients N3). Tumours were histologically determined as squamous cell carcinoma with keratinisation in 4 patients (15%), as squamous cell carcinoma without keratinisation in 13 patients (50%) and as undifferentiated carcinoma in 9 patients (35%). 16 patients showed histological grade 2 and ten patients showed grade 3. EBV-status in tumour biopsies before radio(chemo)therapy was determined as follows: 17 patients were EBV positive, six negative, and in three patients, status was missing because it was not determined in the early 1990s, and there were no available histological-blocs for retrospective analysis. Patient characteristics were summarised in Table [1](#Tab1){ref-type="table"}.Table 1Pre-treatment characteristics of patients entered in the studyCharacteristicNo. of patients (%)Gender Male21 (81) Female5 (19)UICC stage II2 (8) III9 (34) IV15 (58)T-Status 12 (8) 26 (23) 35 (19) 413 (50)N-status 06 (23) 11 (4) 216 (62) 33 (11)Histologic grade 216 (62) 310 (38)EBV-Status in tumour Positive17 (65) Negative6 (23) Not known3 (12)Interferon therapy Yes6 (23) No20 (77)Concomitant chemotherapy Yes13 (50) No13 (50)

Pre-treatment examinations {#Sec4}
--------------------------

Initial examinations before treatment included medical history, clinical ENT (ear-nose-throat) examination (magnifying laryngoscopy, upper bronchoscopy, esophagoscopy, ear-nose-throat endoscopy) with biopsies in potential mucosal primary sites, complete blood counts, biochemical analysis, electrocardiogram, chest X-rays, abdominal ultrasound, and CT scans of the thorax and the head and neck with contrast medium. Whenever achievable a MRI scan of the head and neck with contrast medium was carried out. Pre-treatment characteristics of patients entered in study are concluded in Table [1](#Tab1){ref-type="table"}.

Treatment {#Sec5}
---------

In summary, due to changes in treatment protocols and technical developments over the years, there are differences in cumulative dose, treatment techniques, and accompanying therapies (chemotherapy, interferon-beta). Details are summarised in Table [2](#Tab2){ref-type="table"}.Table 2Protocols used for the treatment of NPC in the respective time-periodsPeriod*n*HistologyChemotherapyRadiotherapy techniqueIFN-beta1992--199552 undiff. and 3 SCCCarboplatin 50 mg/(m² TBSA every radiotherapy day)2 fractions/day with 2.1 Gy, split-course regimen up to 56.7 Gy (including primary tumour region and neck)--3SCC--3D-conformal RT up to 70 Gy with 2 Gy single dose (including primary tumour and neck up to 50 and 20 Gy boost to the primary tumour region and involved nodes)--1996 --20003SCC2 patients: taxol 30 mg/(m^2 ^TBSA week)3D-conformal RT up to 70 Gy (see above)--1 patient: two courses of cisplatin \[20 mg/(m^2^ TBSA days 1--5\] and 5-FU \[1,000 mg/(m^2^ TBSA days 1--5\] in the first and fifth week of radiotherapy21 SCC and 1 undiff.--3D-conformal RT up to 70 Gy (see above)--2001--20086Undiff.2 patients: three courses of neoadjuvant chemotherapy at intervals of 4 weeks with methotrexate 120 mg/(m^2 ^TBSA) + cisplatin 100 mg/(m^2^ TBSA) on day 1, and 5-FU 1,000 mg/(m^2^ TBSA days 1--5), analogous NPC-91-GPOH protocol3D-conformal RT up to 60 Gy with 2 Gy single dose (including primary tumour and neck up to 50 and 10 Gy boost to the primary tumour region and involved nodes)Adjuvant IFN-beta (10^5^ IU/kg bodyweight three times per week for 6 months, started within 4 weeks after completion of RT and recovery from acute radiation-induced side-effects)4 patients: three courses of neoadjuvant chemotherapy at intervals of 4 weeks with cisplatin \[100 mg/(m^2^ TBSA day 1)\] and 5-FU \[1,000 mg/(m^2^ TBSA days 1--5\] and two courses of concomitant cisplatin \[20 mg/(m^2^ TBSA days 1--3\] in the first and fifth week of radiotherapy, analogous NPC-2003-GPOH protocol7SCC4 patients: concomitant cisplatin 6 mg/(m² TBSA every radiotherapy day)3D-conformal RT up to 70 Gy (see above)--3 patients: concomitant cisplatin 20 mg/(m² TBSA) for 5 days in first and fifth week of irradiation*SCC* squamous cell carcinoma, *IFN-beta* interferon-beta, *undiff.* undifferentiated carcinoma

Treatment monitoring and follow-up {#Sec6}
----------------------------------

Toxicity was monitored weekly during radio(chemo)therapy and every second week following therapy until disappearance of acute side effects. Subsequently, chronic toxicity was monitored at least yearly for the first 5 years after radio(chemo)therapy. Side effects were classified according to the CTC score for acute (Cox et al. [@CR10]; Trotti et al. [@CR43]) and according to the LENT scoring system for chronic side effects (Hendry et al. [@CR16]; Rubin et al. [@CR38]).

After radiochemotherapy, remission was evaluated by clinical ENT-examination (ear-nose-throat endoscopy, magnifying laryngoscopy, whenever necessary upper bronchoscopy, and esophagoscopy) and a computed tomography with contrast medium. Complete remission was defined as the complete regression of all tumour manifestations. Afterwards, patients underwent quarterly clinical ENT-examination, complete blood counts, biochemical analysis, chest X-rays, abdominal ultrasound or a computed tomography of the head and neck, if necessary. Biopsies were taken from suspect findings to receive histological confirmation of tumour growth.

Statistics {#Sec7}
----------

Survival probabilities were calculated from the day of histological diagnosis. The Kaplan--Meier product-limit method was used to determine overall survival and loco-regional control. Loco-regional control was defined as the absence of local or regional recurrence or progression. The possible impact of chemotherapy or EBV-status on prognosis was estimated by univariate analysis (log-rank test). Statistical analyses were generated with the programme STATISTICA for windows version 6.1 \[StatSoft, Inc. (2002)\].

Results {#Sec8}
=======

After a median follow-up duration of 96 months (range 9--198 months), 17 patients (65%) remained alive. Death has occurred in nine patients (35%); while four of these died from primary tumour, five died from intercurrent disease \[one-second primary (intracranial neuroblastoma), one pulmonary embolism, one heart attack, and two not known\]. Collectively, the 5-year overall survival rate was 74% (life table analysis is shown in Fig. [1](#Fig1){ref-type="fig"}). Notably, all six patients treated according to the GPOH protocols with adjuvant interferon-beta are still alive until the end of the follow-up.Fig. 1Kaplan--Meier plot of overall survival for all patients, and for patients with undifferentiated NPC treated with adjuvant IFN-beta, calculated from the time of histopathological diagnosis

Loco-regional relapse occurred in four patients (three local, one regional); median time to relapse was 22 months (range 6.4--36.8). Collectively, the 5-year loco-regional control rate was 87%. One of the patients with loco-regional relapse was treated according to the NPC-91-GPOH protocol. In this patient, local relapse after 36.8 months was treated with salvage chemotherapy because of inoperability in the year 2005. This patient was still alive at the end of the follow-up without another relapse after complete remission through salvage chemotherapy. The three other patients with loco-regional relapse were squamous cell carcinomas and treated with concomitant radiochemotherapy. In the first patient, local relapse after 3 months was treated with salvage chemotherapy. This patient died 6.4 months after salvage treatment because of additional cervical metastases and general constitution. In the second patient, radiochemotherapy after macroscopic complete tumour resection was stopped on demand of the patient because of severe acute side effects after 28.8 Gy and one chemotherapy course. Local relapse occurred 19 months after radiochemotherapy. As salvage therapy, this patient underwent surgery and stayed alive until the end of the follow-up. Regional relapse after 6.4 months in third patient was treated with salvage chemotherapy. This patient died 2 months after the salvage treatment because of the general constitution (loco-regional control analysis is shown in Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Kaplan--Meier plot of loco-regional control for all patients, and for patients with undifferentiated NPC treated with adjuvant IFN-beta, calculated from the time of histopathological diagnosis

Distant metastases occurred in two patients (one pulmonary and one mediastinal). In one patient, a secondary malignant tumour in the form of an intracranial neuroblastoma was recorded in 2004 after treatment of her NPC in 1995. After chemotherapy this patient stayed alive until the end of the follow-up without another relapse of the neuroblastoma or the NPC.

Subgroup analyses concerning chemotherapy showed better overall survival and loco-regional control rates for radio(chemo)therapy compared to radiotherapy alone \[81 vs. 68.5% (*P* = 0.54), and 100 vs. 72.7% (*P* = 0.072), respectively\]. However, the differences were not statistically significant; this may be due to the small sample size. Similarly, the EBV-status in the tumour biopsies before radio(chemo)therapy had no impact on prognosis.

Toxicity {#Sec9}
--------

In summary, therapy was well tolerated. There were no treatment-related deaths and no grade 4 toxicities. Grade 3 mucositis/dysphagia was seen in six patients. In an additional patient, grade 3 mucositis and skin reaction occurred. Sole haematological toxicity in form of leukopenia ≥grade 3 appeared in two patients. In another two patients mucositis/dysphagia and haematological toxicity ≥grade 3 (leukopenia and anaemia or leukopenia alone) was observed. Three of these patients received a concomitant radiochemotherapy; the other one was treated with irradiation alone. Thus, toxicity-related changes of the therapy schedule were only infrequently necessary \[one patient did not receive the second of planned two courses cisplatin, one patient paused 7 days during a 5-FU and cisplatin chemotherapy, and one patient missed two infusions of cisplatin 6 mg/(m^2^ TBSA day)\]. Because of severe side effects (mucositis and dysphagia), radiochemotherapy after macroscopic complete tumour resection was stopped on demand of the patient because of severe acute side effects after 28.8 Gy, and one chemotherapy course (see above), in another patient, the boost dose was reduced from 20 to 14 Gy because of the dose at the organs at risk. In the six patients treated with neoadjuvant chemotherapy according to the GPOH-protocols, no side effects grade 2 or higher were observed (one patient grade 1 anaemia and leukopenia only). Adjuvant interferon-beta therapy was well tolerated and could be applied regularly by all six treated patients. Four patients developed fever during first or second application, but adapted on the therapy in following courses without any further serious side effects. Late toxicity graded ≥2 was recorded in ten patients (loss of taste: 4 patients; loss of taste and xerostomia: three patients; xerostomia alone: two patients; xerostomia, fibrosis and lymph oedema: one patient, fibrosis did not significantly impair quality of life during follow-up). One of these patients was treated with neoadjuvant chemotherapy, six with concomitant radiochemotherapy and three with irradiation alone. There was no ototoxicity assessed in our patient population.

Discussion {#Sec10}
==========

Our data confirm the known fact that NPC can be cured by radio(chemo)therapy and has a significant better prognosis compared to the other squamous cell head and neck cancer entities (oral cavity, oropharynx, hypopharynx, larynx). Thereby, our disease overall survival (74% after 5 years), and loco-regional control rates (87% after 5 years) are comparable to the literature (Table [3](#Tab3){ref-type="table"}). Furthermore, to our knowledge, we are the first in literature to report the treatment of adult NPC patients with radiochemotherapy followed by adjuvant administration of interferon-beta according to the GPOH protocols for childhood NPC \[NPC-1991 GPOH (Mertens et al. [@CR32]; Mertens et al. [@CR31]), NPC-2003 GPOH\]. Our experiences show that this regime is feasible without unacceptable toxicity in adult patients. Furthermore, the fact that all our patients treated with this regime are still alive at the end of our analysis is encouraging and demand further prospective studies in this field.Table 3Overall Survival and Loco Regional Control of different radio(chemo)therapy regimens for treatment of Nasopharyngeal CarcinomaStudyPatients (n)TreatmentRT-dose (Gy)Loco Regional ControlOverall SurvivalPresent study26R(C)T56--70.45 years: 87%5 years: 74%Sequent CT, R(C)T and IF (for undifferentiated NPC) 5 years: 100%NPC-91-GPOH (Mertens et al. [@CR32])59Sequent CT, RT and IF59.49 years: 91%9 years: 95%Chua 1998 (Chua et al. [@CR9])335RT5 years: 71%5 years: 42%C + RT66--745 years: 78%5 years: 48%Ma 2001 (Ma et al. [@CR29])456RT68--725 years: 49%5 years: 56%C + RT5 years: 59%5 years: 63%Dimery 1993 (Dimery et al. [@CR14])47C + RT68--726 years: 73%6 years: 67%Zhang 2005 (Zhang et al. [@CR33])115RT70--742 years: 83%2 years: 77%RCT2 years: 96%2 years: 100%Chan 2005 (Chan et al. [@CR6])350RT66--765 years: 52%5 years: 59%RCT5 years: 62%5 years: 72%Wee 2005 (Wee et al. [@CR44])189RT703 years: 53%3 years: 65%RCT3 years: 72%3 years: 80%*RT* radiotherapy; *CT* chemotherapy; *IF* interferon-beta, *C* *+* *RT* neoadjuvant chemotherapy + radiotherapy; *RCT* radiochemotherapy; *OS* overall survival, *DSS* disease specific survival

However, the optimal radiochemotherapy schedule for NPC has not been defined yet. Besides good treatment results obtained by concomitant radio(chemo)therapy, local relapse is still a major problem (Daoud and Frikha [@CR11]; Lu [@CR24]; O'Sullivan [@CR34]; Yarney et al. [@CR46]). One possibility to improve LRC, and thus OS, is dose escalation of radiotherapy, and several authors propagate this in radiotherapy for NPC (Lauve et al. [@CR20]; Lu et al. [@CR25]). However, this is difficult to achieve in the nasopharyngeal region due to close critical organs, e.g. optical nerve, chiasm, and brainstem. Further optimisation and establishment of recent advantages in radiotherapy may help to apply higher doses, e.g. by brachytherapy (Lu et al. [@CR25]; Ng et al. [@CR33]), IMRT (Lu et al. [@CR26]; Parliament et al. [@CR35]), and stereotactic radiotherapy (Low et al. [@CR23]; Wu et al. [@CR45]).

On the other hand, in the NPC-91-GPOH study, excellent overall survival---95% after 9 years---and disease-free survival---91% after 9 years, respectively, could be obtained with a total radiation dose of 59.4 Gy only (Mertens et al. [@CR32]). In the current NPC-2003-GPOH study, a further dose reduction of 54 Gy is intended for children with complete tumour regression after neoadjuvant chemotherapy. These encouraging results of the GPOH studies show that possibly in undifferentiated nasopharyngeal carcinoma a further dose escalation is not necessary when adjuvant interferon beta and neoadjuvant chemotherapy are given, and indicates that both should also be applied in adult patients, as well as in childhood NPC. This is of special importance as the lower the radiation dose the lower the risk for acute and chronic radiation-induced side effects and the higher the quality of life for the patients. The question, whether a reduction of the radiation dose while intensifying systemic therapy to reduce the risk for radiation-induced side effects without compromising tumour control is also currently under investigation in a multicenter phase III study---Paccis-RCT (Paclitaxel-Cisplatin-Radiochemotherapie)---of the "Deutsche Krebshilfe" for advanced head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, larynx): In this study, the standard arm includes 70.2 Gy irradiation (3 weeks 5 × 2 Gy/week and 3 weeks 2 × 1.4 Gy/day, five times per week) with additional 5-FU \[600 mg/(m^2^ TBSA day)\] and cisplatin \[20 mg/(m^2^ TBSA day)\] for 5 days in week 1 and 5 of irradiation. In the experimental arm, radiation dose is reduced to 63.6 Gy (3 weeks 5 × 2 Gy/week and 2.5 weeks 2 × 1.4 Gy/day, five times per week) plus intensified concomitant chemotherapy (cisplatin 20 mg/(m^2^ TBSA day) for 5 days in week 1 and 5; taxol 25 mg/(m^2^ TBSA day) on day 1, 4, 8, 12, 26, 30, 33, and 37). Aim of the study is, to test, whether the reduction of the radiation dose with intensified chemotherapy results in fewer side effects without compromising tumour control.

In comparison to other tumour entities of the head and neck, the NPC is distinctively sensible to radio- and chemotherapy, and can be cured without surgery in locally advanced stages at a high percentage (Brennan [@CR3]). One hypothesis for this fact is the frequent viral association with Ebstein--Barr virus infection which is reported to be a high frequent factor in tumour genesis in NPC. For example, Lin et al. ([@CR22]) found a plasma DNA of the EB virus in 94 of 99 patients with NPC but not in 40 healthy or cured patients. Analogue findings were reported in other studies (Raab-Traub [@CR36]; Zhou et al. [@CR48]). Similarly, other tumour entities, like anal or cervix carcinoma are also well known to be virus associated and radio(chemo)therapy sensible too (Bosch et al. [@CR2]; Castellsague [@CR4]; Robinson et al. [@CR37]; Smith et al. [@CR39]). Furthermore, it was shown that quantification of plasma EBV DNA and other serum parameters like anti-EBV antibodies even allows patient monitoring with NPC under treatment and can predict outcome and probability of recurrence (de-Vathaire et al. [@CR12]; Guigay [@CR15]; Lin et al. [@CR22]). Unfortunately, we could not show this in our analysis due to the fact that EBV parameters despite the initial EBV-status in the tumour were not collected in our patients. However, we now started to monitor EBV DNA and serum parameters in all patients treated with NPC at our department now and in the future. Through this, further analyses including bio-monitoring and controls in the course of treatment will be possible.

In summary, our data affirm that NPC in adults are curable by primary radio(chemo)therapy. Furthermore, our data indicate that adjuvant interferon-beta application in undifferentiated NPC in adults is feasible and shows promising results. Further prospective clinical trials are needed to finally establish adjuvant interferon beta in curative treatment of adult NPC.
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